detorubicin profile

ID Source	ID
PubMed CID	6917660
CHEMBL ID	2104401
SCHEMBL ID	8642
MeSH ID	M0067818

Synonym
rp-33921
dea-14-dnr
detorubicin
rp 33921
brn 4637868
glyoxylic acid 3(sup 2)-ester with doxorubicin, 2-(diethyl acetal)
(((2s,4s)-4-(3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)carbonyl)methylglyoxylat-2-(diethylacetal)
(1s,3s)-3-(diethoxyacetoxyacetyl)-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,36-tridesoxy-alpha-l-lyxo-hexopyranosid
detorubicina [inn-spanish]
detorubicine [inn-french]
acetic acid, diethoxy-, 2-(4-((3-amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester, (2s-cis)-
detorubicinum [inn-latin]
detorubicin [inn]
66211-92-5
[2-[(2s,4s)-4-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethyl] 2,2-diethoxyacetate
detorubicine
unii-822ec3xejz
detorubicina
822ec3xejz ,
detorubicinum
CHEMBL2104401
SCHEMBL8642
acetic acid, 2,2-diethoxy-, 2-((2s,4s)-4-((3-amino-2,3,6-trideoxy-.alpha.-l-lyxo-hexopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl ester
glyoxylic acid 32-ester with doxorubicin, 2-(diethyl acetal)
nsc 292652; rp 33921
Q27269295
DTXSID601024380

Excerpt	Reference	Relevance
"Detorubicin is a new anthracyclin drug which has shown promise in the treatment of these tumors in a previous trial."	( [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone]. Armand, JP; Bui, NB; Cappelaere, P; Chauvergne, J; Durand, M; Gary-Bobo, J; Guerrin, J, 1982)	1.19

Excerpt	Reference	Relevance
" On an equimolar basis DET appears to be less toxic than DOX for both the pluripotent stem cells and the granulocytic progenitor cells."	( Comparative toxicity of detorubicin and doxorubicin, free and DNA-bound, for hemopoietic stem cells. Huybrechts, M; Trouet, A, 1980)	0.57

Excerpt	Reference	Relevance
" Detorubicin can thus be considered a prodrug of Adriamycin with very distinct pharmacokinetic and perhaps therapeutic properties."	( Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin. Baurain, R; Deprez-de Campeneere, D; Trouet, A, 1979)	1.41

Bioassays (19)

Assay ID	Title	Year	Journal	Article
AID1079944	Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079948	Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079945	Animal toxicity known. [column 'TOXIC' in source]
AID1079949	Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079934	Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932	Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079931	Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079937	Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079947	Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079933	Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079939	Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079943	Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079940	Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079942	Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079938	Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079935	Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079941	Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079946	Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079936	Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	15 (93.75)	18.7374
1990's	1 (6.25)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	3 (16.67%)	5.53%
Reviews	1 (5.56%)	6.00%
Case Studies	1 (5.56%)	4.05%
Observational	0 (0.00%)	0.25%
Other	13 (72.22%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
taurine [no description available]	1.97	1	0	amino sulfonic acid; zwitterion	antioxidant; Escherichia coli metabolite; glycine receptor agonist; human metabolite; mouse metabolite; nutrient; radical scavenger; Saccharomyces cerevisiae metabolite
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	1.97	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	1.97	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
lomustine [no description available]	1.97	1	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	1.97	1	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	1.97	1	0	benzamides; hydrazines	antineoplastic agent
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	1.97	1	0	aziridines
cytarabine [no description available]	1.96	1	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	6.4	16	3	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	1.97	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
vindesine Vindesine: Vinblastine derivative with antineoplastic activity against CANCER. Major side effects are myelosuppression and neurotoxicity. Vindesine is used extensively in chemotherapy protocols (ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS).	1.97	1	0	methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; primary carboxamide; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	1.96	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	1.97	1	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
1-(2-chloroethyl)-3-(2-(dimethylaminosulfonyl)ethyl)-1-nitrosourea [no description available]	1.97	1	0
methotrexate [no description available]	8.34	1	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
aclarubicin Aclarubicin: An anthracycline produced by Streptomyces galilaeus. It has potent antineoplastic activity.. aclacinomycin A : An anthracycline antibiotic that is produced by Streptomyces galilaeus and also has potent antineoplastic activity.	1.96	1	0	aminoglycoside; anthracycline; methyl ester; phenols; polyketide; tetracenequinones; trisaccharide derivative; zwitterion	antimicrobial agent; antineoplastic agent; apoptosis inducer; bacterial metabolite; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
valrubicin [no description available]	1.96	1	0	anthracycline; trifluoroacetamide
glycosides [no description available]	1.95	1	0
tamoxifen [no description available]	1.97	1	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	8.76	2	1	dacarbazine

Condition	Relationship Strength	Studies	Trials
Cancer of Esophagus [description not available]	3.34	1	1
Cancer of Head [description not available]	3.75	2	1
Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS.	3.34	1	1
Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)	3.75	2	1
Malignant Melanoma [description not available]	9.44	5	1
Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	4.44	5	1
Leukemia L 1210 [description not available]	2.36	2	0
Cardiac Diseases [description not available]	4.26	4	1
Cardiac Failure [description not available]	2.36	2	0
Heart Diseases Pathological conditions involving the HEART including its structural and functional abnormalities.	4.26	4	1
Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	2.36	2	0
Leucocythaemia [description not available]	2.36	2	0
Acute Disease Disease having a short and relatively severe course.	1.96	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.36	2	0
Breast Cancer [description not available]	1.95	1	0
Carcinoma, Anaplastic [description not available]	1.95	1	0
Benign Neoplasms [description not available]	2.65	3	0
Cancer of the Uterus [description not available]	1.95	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.95	1	0
Carcinoma A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.	1.95	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	2.65	3	0
Uterine Neoplasms Tumors or cancer of the UTERUS.	1.95	1	0
Germinoblastoma [description not available]	1.95	1	0
Experimental Neoplasms [description not available]	1.95	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	1.95	1	0
Cardiomyopathies, Primary [description not available]	1.95	1	0
Cancer of Skin [description not available]	2.36	2	0
Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS).	1.95	1	0
Skin Neoplasms Tumors or cancer of the SKIN.	2.36	2	0
Carcinoma, Oat Cell [description not available]	1.97	1	0
Cancer of Lung [description not available]	2.37	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.37	2	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	1.97	1	0
Alopecia Cicatrisata [description not available]	3.35	1	1
Peritoneal Carcinomatosis [description not available]	3.35	1	1
Neoplasms, Pleural [description not available]	3.35	1	1
Emesis [description not available]	3.35	1	1
Alopecia Absence of hair from areas where it is normally present.	3.35	1	1
Mesothelioma A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)	8.35	1	1
Nausea An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.	3.35	1	1
Peritoneal Neoplasms Tumors or cancer of the PERITONEUM.	3.35	1	1
Vomiting The forcible expulsion of the contents of the STOMACH through the MOUTH.	3.35	1	1
Leukocytopenia [description not available]	1.96	1	0
Lymph Node Metastasis [description not available]	1.96	1	0
Thrombopenia [description not available]	1.96	1	0
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	1.96	1	0
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	1.96	1	0

detorubicin

Cross-References

Synonyms (27)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioassays (19)

Research

Studies (16)

Study Types

detorubicin

Cross-References

Synonyms (27)

Research Excerpts

Overview

Toxicity

Pharmacokinetics

Bioassays (19)

Research

Studies (16)

Study Types

Related Drugs (20)

Related Conditions (47)